James Halstead Reports Slight Rise in Fiscal 2023 Pretax Profit

1 Mins read

Manufacturer and distributor of commercial floor coverings, James Halstead, announced that its pretax profit for fiscal 2023 saw a slight increase despite inflationary pressure on costs. The company also reported a growth in revenue and a raised dividend payout.

Profit and Revenue Growth

For the year ending June 30, the company’s pretax profit reached £52.099 million ($63.6 million), a slight rise from the £52.063 million reported the previous year. Furthermore, revenue experienced a 4% increase, reaching £303.6 million.

Positive Market Demand

James Halstead attributed its positive financial results to strong demand in several key markets. The company expressed satisfaction with both profit levels and earnings per share, which reached record highs.

Increased Dividend Payout

In line with its performance, the board proposed an increased final dividend payout of 5.75 pence per share, up from 5.50 pence in the previous year.

Confidence in Future Prospects

Looking ahead, James Halstead expressed confidence in its prospects for the current fiscal year. Overseas turnover is expected to account for 60% to 65% of total turnover, with continued growth anticipated. The company cited factors such as improved global shipping availability, a strong balance sheet, and a proven business model as supporting its positive outlook.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

34 + = 40